Lucentis Content page

Who is LUCENTIS for?

LUCENTIS^® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (AMD).

Important LUCENTIS Safety Information

Like any prescription medication, LUCENTIS is not for everyone. You should not use LUCENTIS if you have an infection in or around the eye.

Like other injections given into the eye, serious eye infection (endophthalmitis) and detached retina have occurred with LUCENTIS. Increases in eye pressure have been seen within 1 hour of an injection. Your eye doctor should monitor your eye pressure and eye health during the week after the injection. If your eye becomes red, sensitive to light, painful, or has a change in vision, you should seek immediate care from your eye doctor.

Although uncommon, conditions associated with eye- and non–eye-related blood clots (arterial thromboembolic events) may occur.

Serious side effects related to the injection procedure were rare. These included serious eye infection, detached retina, and cataract. Other uncommon serious side effects included inflammation inside the eye and increased eye pressure.

The most common eye-related side effects were red eye, eye pain, small specks in vision, the feeling that something is in your eye, and increased tears. The most common non–eye-related side effects were high blood pressure, nose and throat infection, and headache.

LUCENTIS is for prescription use only.

Individual results with LUCENTIS may vary.

Please see LUCENTIS full Prescribing Information.

*First Name:
*Last Name:
*E-mail Address:
*Re-type E-mail Address:
*Required
Note: If you do not have an e-mail address, please call 1-877-9-AMDINFO (1-877-926-3463) to enroll.
Street Address Line 1:
Street Address Line 2:
City:
State:
*ZIP :
Phone:	- -
Date of Birth :	- -
*Required fields
This program is a service of Genentech and is intended for U.S. residents only. You must be 18 years of age or older to submit registration or survey information. If you are under the age of 18 and wish to register to obtain further information or be included in a survey, then your parent or legal guardian must register to obtain the information or to participate in the survey.

Please note: If you are requesting information for a friend or family member, please fill out the remainder of these questions on his/her behalf.
With what type of macular degeneration have you been diagnosed?
Wet Dry Not sure

Have you received any treatment for your macular degeneration?
Yes No

Which of the following treatments have you received? (Please check all that apply.)
Visudyne^® (verteporfin for injection) PDT*
Hot laser treatment (please specify)
Macugen^® (pegaptanib sodium injection)^†
LUCENTIS^® (ranibizumab injection)
Date of your first injection: - -_{(ex. 2006)}
Other injection (please specify)
Alternative therapy (please specify)
*Visudyne is a registered trademark of Novartis Pharmaceuticals Corporation. ^†Macugen is a registered trademark of (OSI) Eyetech, Inc., and Pfizer Inc.